TD Cowen lowered the firm’s price target on Incyte (INCY) to $86 from $88 and keeps a Buy rating on the shares. The firm said they reported a strong Q1 and multiple incrementally positive povorcitinib updates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue